Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
|Videos|April 11, 2022
EEG Talk
EEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. New episodes featuring special guests in the field are posted regularly on Mondays.
Advertisement
———————————————
EEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. Hosted by Fábio A. Nascimento, MD, and Brandon Westover MD, PhD, each episode typically covers a single EEG review with another expert in the field as a superstar guest. All episodes are publicly available on the show's YouTube channel.
Advertisement
Related to this article
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Here's some of what is coming soon to NeurologyLive® this week.
A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
Advances in Spinal Cord MRI for Multiple Sclerosis: Julien Cohen-Adad, PhD
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5